Clinical trials: Donor Lymphocyte Infusion
Acute Myeloid Leukemia
Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
The purpose of this study is to see the effects of an investigational combination treatment of venetoclax, azacitidine, and donor lymphocyte infusion (DLI) in patients with high-risk AML receiving allogeneic hematopoietic cell…
- Trial name
- NCT06158100
- Testing
- Venetoclax, Azacitidine, Donor Lymphocyte Infusion
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Antonio M Jimenez Jimenez
Hematological Malignancies
Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies
The aim of the study is to obtain immune reconsitutuion as well as reduction of infective episodes and disease relapse in patient with haematological malignancies who underwent SCT(and subsequent T lymphocytes infusions) and…
- Trial name
- NCT00423124
- Testing
- HSV-TK
- Where
- 8 sites in Germany, Greece and 3 more
- Volunteers
- 57 people
- Sponsor
- AGC Biologics S.p.A.
Hematologic Malignancy, Haplo-identical Stem Cell Transplantation
Prophylactic CD45RA-depleted DLI After Haploidentical Transplantation/RIC
To assess safety of prophylactic escaladed dose of T naïve depleted (CD45RA depleted donor lymphocyte infusion, in patients with malignant hemopathie who received an allogeneic stem cell transplant from an haplo-identical donor…
- Trial name
- NCT05066412
- Testing
- CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- University Hospital, Geneva
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This pilot phase II trial studies how well giving donor T cells after donor stem cell transplant works in treating patients with hematologic malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Trial name
- NCT01839916
- Testing
- therapeutic allogeneic lymphocytes, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Chicago
Acute Myeloid Leukemia
Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is a curative option for patients with acute myeloid leukemia (AML).
- Trial name
- ELIT-AML01 (NCT03597321)
- Testing
- prophylactic donor lymphocyte infusion (DLI)
- Where
- France
- Volunteers
- 124 people
- Sponsor
- Institut Paoli-Calmettes
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
Background: Allogeneic hematopoietic stem cell transplantation (allotransplant) has been used to treat many kinds of cancer that develop in cells from the blood or immune system.
- Conditions
- Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemias, Multiple Myeloma With Plasmacytoma
- Trial name
- NCT00984165
- Testing
- Single fraction radiation, Donor Lymphocyte Infusion (DLI), Apheresis
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy such as fludarabine use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006233
- Testing
- therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Donor Lymphocyte Infusion, Peripheral Blood Stem Cell Transplantation
Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies
Unmanipulated allogenic peripheral blood stem cell transplantation (allo-PBSCT) has been an established treatment to cure high-risk leukemia/lymphoma.
- Conditions
- Donor Lymphocyte Infusion, Peripheral Blood Stem Cell Transplantation, Relapse, Graft-versus-host Disease
- Trial name
- NCT03771222
- Testing
- Prophylactic DLI
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese PLA General Hospital